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Abstract
Glioblastoma (GBM) contains stem-like cells (GSCs) known to be
resistant to ionizing radiation and thus responsible for therapeu-
tic failure and rapidly lethal tumor recurrence. It is known that
GSC radioresistance relies on efficient activation of the DNA
damage response, but the mechanisms linking this response with
the stem status are still unclear. Here, we show that the MET
receptor kinase, a functional marker of GSCs, is specifically
expressed in a subset of radioresistant GSCs and overexpressed
in human GBM recurring after radiotherapy. We elucidate that
MET promotes GSC radioresistance through a novel mechanism,
relying on AKT activity and leading to (i) sustained activation
of Aurora kinase A, ATM kinase, and the downstream effectors of
DNA repair, and (ii) phosphorylation and cytoplasmic retention of
p21, which is associated with anti-apoptotic functions. We show
that MET pharmacological inhibition causes DNA damage accu-
mulation in irradiated GSCs and their depletion in vitro and in
GBMs generated by GSC xenotransplantation. Preclinical evidence
is thus provided that MET inhibitors can radiosensitize tumors
and convert GSC-positive selection, induced by radiotherapy, into
GSC eradication.
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Introduction
Treatment of GBM, a rapidly lethal primary brain tumor, has little
advanced in the last decade. Although the genetic and molecular
features of the disease have been elucidated, the high degree of
inter- and intratumor heterogeneity restrains the use of targeted
therapies (Brennan et al, 2013; Ene & Holland, 2015). As a result,
GBM standard of care is still based on maximal but often incomplete
surgical resection, combined with chemoradiotherapy (Stupp et al,
2009). The short-lived therapeutic response has been associated
with the finding that ionizing radiations (IR) destroy the tumor bulk,
but not GSCs, which drive tumor recurrence (Bao et al, 2006). The
higher radioresistance of GSCs, as compared with non-stem cells,
correlates with hyperactivation of the DNA damage response
(DDR), and escape from apoptosis (Bao et al, 2006; Cheng et al,
2011). Moreover, it has been envisaged that radioresistance can rely
on signaling from tyrosine kinase receptors, such as the frequently
amplified EGFR (Squatrito & Holland, 2011), but the issue has not
been addressed in GSCs.
Recently, we and others showed that MET, the HGF receptor,
sustains radioresistance of conventional cell lines (Lal et al, 2005;
De Bacco et al, 2011). We then showed that MET is expressed in
~40% of GSC lineages, derived as neurospheres (i.e. in vitro cultures
enriched in stem and progenitor cells) from GBM patients (De Bacco
et al, 2012). Interestingly, these “MET-pos-NS” usually lack EGFR
amplification and display a mesenchymal or proneural transcrip-
tional profile (De Bacco et al, 2012), according to Verhaak et al
(2010). We also showed that, although clonal, MET-pos-NS contain
cells expressing different levels of MET. The sorted METhigh and
METneg subpopulations display opposite features, with METhigh
retaining GSC properties such as (i) long-term self-propagating and
multi-potential differentiation ability in vitro; (ii) tumorigenic prop-
erty in vivo; and (iii) ability to reconstitute a mixed METhigh/METneg
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population in vitro and in vivo. In contrast, the METneg subpopula-
tion lacks the above properties and displays prodifferentiating
features (De Bacco et al, 2012). Thus, we concluded that MET
marks a cell subpopulation that regenerates self-renewing MET-
positive cells, and a progeny losing GSC properties along with
MET expression. Finally, we showed that MET is a functional
marker, as HGF sustains GSC self-renewal (De Bacco et al, 2012).
Accordingly, other studies showed that MET is a marker for
prospective GSC isolation from patients (Joo et al, 2012) and
sustains the GSC phenotype by upregulating reprogramming
transcription factors (Li et al, 2011).
On these premises, we investigated whether MET is a functional
marker of GSC radioresistance, and whether MET could be exploited
as a therapeutic target to achieve radiosensitization of GBM by
depletion of its GSC component.
Results
Genetic and phenotypic characterization of a large panel of
neurospheres and correlations with radioresistance
We investigated whether patient-derived GSCs, propagated as NS,
displayed greater radioresistance than non-stem/differentiated cells
of the same lineage and whether radioresistance could be preferen-
tially associated with specific genetic alterations or transcriptional
profiles. A panel of 106 NS derived from primary GBM underwent
analysis of the most frequent GBM genetic alterations such as EGFR
amplification (EGFRamp), PTEN inactivation by deletion or mutation
(PTENloss), TP53 mutation, and NFKBIA deletion. NS were then
classified as proneural, classical, or mesenchymal by transcriptional
profiling, according to the Verhaak’s signature (Verhaak et al,
2010). A panel of 20 NS equally distributed among the three
subtypes was chosen (Appendix Tables S1 and S2). The response of
these NS to therapeutic doses of IR was assessed and compared with
that of astrocytes (SVG, NHA) and GBM cell lines (U251, SNB19),
and the same NS cultured in prodifferentiating conditions (Galli
et al, 2004; De Bacco et al, 2012). In dose–response and time–
course viability experiments, all NS invariably displayed higher
radioresistance than astrocytes or GBM cell lines, or the NS
pseudodifferentiated progeny (Figs 1A and B and EV1A and
Appendix Fig S1A). No significant viability change was observed
among different NS (Fig 1A), nor it was associated with any of the
genetic alterations tested or any transcriptional subtype (Fig EV1B
and C).
Next, NS radioresistance was correlated with the ability to evoke
DDR. Phosphorylation of histone H2AX (cH2AX), a key step in the
nucleation of DNA repair complex at double-strand breaks (DSBs),
was measured by flow cytometry (Olive, 2004). Early after irradia-
tion, cH2AX levels were comparable in NS, astrocytes, GBM cell
lines, and NS-derived pseudodifferentiated cells (~10-fold over basal
levels). Within 6 h, cH2AX resolution occurred in NS, indicating
DSB repair, while cH2AX persisted, or even increased in the NS-
derived pseudodifferentiated cells, suggesting DSB persistence
(Fig 1C and Appendix Fig S1B). Consistently, comet assays showed
that, while a low level of DNA damage was detectable in NS 24 h
after irradiation, heavy damage remained in astrocytes, GBM cell
lines, and, mainly, in the NS pseudodifferentiated progeny (Fig 1D).
The greater ability of NS to repair DSBs, as compared with dif-
ferentiated cells, was found to correlate with increased activation of
two crucial DDR signal transducers: (i) ATM, the apical kinase
unleashed by DNA damage sensors, responsible for H2AX phospho-
rylation (Shiloh & Ziv, 2013); and (ii) the ATM substrate Chk2,
whose activation correlates with GSC radioresistance (Bao et al,
2006) (Fig 1E and Appendix Fig S1C). Accordingly, the DNA recom-
binase RAD51, upregulated at the DDR cascade end and critical for
homologous recombination repair (van Gent et al, 2001), was signif-
icantly increased in NS, but not in their pseudodifferentiated
progeny or astrocytes (protein: Fig 1E and Appendix Fig S1C;
mRNA: Fig 1F). As a result, 24 h after irradiation, GBM cell lines or
NS-derived pseudodifferentiated cells displayed cell cycle arrest and
accumulation in G2-M phase, while NS resumed proliferation, as
indicated by the increased number of S-phase cells
(Appendix Fig S1D–F).
Collectively, these findings indicate that GSCs activate DDR more
rapidly and effectively than cells endowed with differentiated
features, resulting in efficient DNA repair, survival, and proliferation
after irradiation.
The neurosphere GSC subpopulation is selected by irradiation
By definition, NS are clones deriving from expansion of single self-
renewing GSCs. However, each NS entails a certain degree of pheno-
typic heterogeneity, which arises within the progeny of the founder
GSC, and implies loss of stem properties, including radioresistance.
We thus investigated whether, within the whole heterogeneous NS,
the GSC subpopulation was more radioresistant than its non-stem
progeny and whether it was positively selected by IR. It is known
that stem-like cells from GBM and other tumors can be identified by
retention of PKH-26 dye (Pece et al, 2010; Richichi et al, 2013).
Figure 1. GSCs are radioresistant.
A Cell viability of NS, GBM, and astrocyte cell lines measured 72 h after irradiation (fold versus non-irradiated cells, ctrl). *: one-way ANOVA, P = 0.0001. n = 2.
B Cell viability of BT308NS and their pseudodifferentiated progeny (BT308 diff) measured 24 h after irradiation (fold versus non-irradiated cells, ctrl). *: t-test,
P = 0.0006. n = 2.
C Flow cytometric analysis of phosphorylated histone H2AX (cH2AX) at the indicated time points after IR (5 Gy, fold versus non-irradiated cells, ctrl). *: one-way ANOVA,
P = 0.03. n = 2.
D Neutral comet assay performed 24 h after IR (5 Gy). Ctrl: non-irradiated cells. Comet tail’s length is proportional to DSB extent.
E Western blot showing phosphorylation of ATM (pATM) and Chk2 (pChk2) and accumulation of RAD51 after IR (5 Gy). Total ATM protein is also shown. Vinculin was
used as a loading control.
F qPCR of RAD51 expression measured in NS, BT308 diff, and astrocytes at the indicated time points after IR (5 Gy, fold versus non-irradiated cells, ctrl). n = 3.
Data information: Data are represented as mean  SEM.
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A panel of NS was stained with PKH-26, showing dye retention in a
variable percentage of cells in each NS (on average ~30%) (Fig 2A
and Appendix Fig S2A). Next, NS were irradiated with a single
(5 Gy) or an equivalent fractionated dose (1.5 Gy × 4 days or
2 Gy × 3 days). After irradiation, the percentage of PKH-26-
retaining cells significantly increased, as well as their mean fluores-
cence intensity (MFI), as compared with non-irradiated cells,
indicating that the stem-like NS subpopulation was enriched (Fig 2A
and Appendix Fig S2A). A stem-like cell enrichment after NS irradia-
tion was also indicated by (i) qPCR evaluation of SOX2 transcrip-
tion, previously associated with the GSC phenotype (Fig 2B) (Li
et al, 2011); (ii) flow cytometric analysis of Olig2, a marker previ-
ously used to characterize mesenchymal/proneural radioresistant
NS (Appendix Fig S2B) (Bhat et al, 2013).
We then showed that irradiation raised the frequency of cells
displaying GSC functional properties, as measured by limiting dilu-
tion assays (LDA) performed in vitro and in vivo. In a representative
panel of NS, irradiation with 5 Gy significantly increased the
frequency of sphere-forming cells (Fig 2C). In a representative NS
(BT308NS), irradiation increased the tumorigenic potential. As
depicted in Fig 2D, NS were irradiated in vitro (NS-IR, p0) and, after
24 h, transplanted subcutis in the mouse (p1). In parallel, an equal
number of non-irradiated NS cells (NS-ctrl) were transplanted as
control. Both NS-IR and NS-ctrl generated tumors (p1) that were
serially passaged by further transplantation of an equal number of
cells (p2). Finally, tumors generated in p2 were passaged as a limit-
ing dilution assay, by transplanting 10–104 cells in p3 mice. The
calculated GSC frequency was ~11-fold higher in tumors originated
from NS-IR, as compared with tumors from NS-ctrl (Fig 2E and F).
In addition, cells were derived from p3 tumors and assessed in an
in vitro LDA, showing that the sphere-forming ability significantly
increased in cells from tumors that originated from NS-IR, as
compared with controls (Fig 2G). In accordance with in vivo and
in vitro evidence of GSC enrichment associated with irradiation, the
median volume of tumors generated by NS-IR, comparable to those
generated by NS-ctrl at p1, increased through serial passages to a
greater extent, as compared with control tumors (Fig EV2A and B).
Finally, an increased GSC frequency was also observed in a second
GBM model. This tumor was established by intracranic injection of
NS, treated in vivo with IR (2 Gy × 3 days), and assessed by in vitro
LDA 62 days after treatment (Fig 2H).
Collectively, these results show that the cell subpopulation
endowed with the clonogenic and tumorigenic properties that qual-
ify GSCs is positively selected by IR.
MET-expressing GSCs are selected by irradiation in
experimental models
We have previously shown that (i) MET is expressed in a subset of
NS (~40%) sequentially derived from primary GBM (MET-pos-NS);
Figure 2. GSCs are positively selected by irradiation.
A Flow cytometric analysis of PKH-26 staining in irradiated BT308NS, 24 h after the last irradiation. The percentage of PKH-26pos cells is indicated. Ctrl: non-irradiated
cells. The mean fluorescence intensity (MFI) was as follow: ctrl, 58.21; 1.5 Gy × 4, 69.35; 2 Gy × 3, 68.20; 5 Gy, 60.29.
B qPCR of SOX2 expression measured in NS 6 h after IR (5 Gy, fold versus non-irradiated cells, ctrl). *: t-test, P < 0.02. n = 3.
C LDA (sphere-forming) measuring the enrichment of GSCs after IR (5 Gy). Ctrl: non-irradiated cells *: v2 test, P < 0.05. n = 2.
D Schematic representation of serial xenotransplantation. Control (NS-ctrl) and irradiated (NS-IR) BT308NS were tested for tumor-initiating ability by serial
subcutaneous injection of the indicated number of cells (p1, n = 4; p2, n = 6; p3, n = 6 for each condition).
E Tumor incidence in the LDA performed in p3 mice, as described in (D).
F Histogram showing the in vivo GSC frequency measured by LDA in p3 tumors. GSC frequency (95% CI) was as follows: NS-ctrl, 1/258.2 (97.67-683.9); NS-IR 1/22.1
(8.05-62.6). *: v2 test, P = 1.6 × 104. n = 6.
G LDA (sphere-forming) measuring the in vitro frequency of GSCs in cells derived from p3 tumors. *: v2 test, P = 0.0006. n = 3.
H LDA (sphere-forming) measuring the in vitro frequency of GSCs in cells derived from intracranial tumors generated by BT463NS and irradiated in vivo (2 Gy × 3 days)
(n = 3). Ctrl: non-irradiated tumors. *: v2 test, P = 2.04 × 1011.
Data information: Data are represented as mean  CI in (C, G, H) or  SEM in (B).
Figure 3. MET-expressing GSCs are selected by irradiation.
A In MET-pos-NS, the METhigh subpopulation retains GSC properties and generates a heterogeneous progeny including also METneg pseudodifferentiated cells.
B LDA (sphere-forming) measuring the GSC frequency after IR (5 Gy) in METhigh and METneg subpopulations sorted from BT308NS. *: v2 test, P = 0.001. n = 2.
C Flow cytometric analysis of MET in irradiated BT308NS, 24 h after the last irradiation (2 Gy × 3 days or a single dose of 5 Gy). Dotted lines: threshold to define the
percentage of MET-expressing cells. Ctrl: non-irradiated cells. The MFI was as follows: ctrl, 18; 2 Gy × 3, 22.77; 5 Gy, 19.49.
D Flow cytometric analysis of MET in BT308NS weekly treated with IR (2 Gy) for 6 weeks. Dotted lines: threshold to define the percentage of MET-expressing cells. Ctrl:
non-irradiated cells.
E Representative immunofluorescence staining of MET (red) on tumors generated by subcutaneous injection of BT308NS irradiated (2 Gy × 3) and explanted 72 h after
the last irradiation. Nuclei are counterstained with DAPI (blue). Ctrl: non-irradiated tumors. Scale bar, 10 µm (63× magnification).
F Left: Quantification of the percentage of MET-expressing cells in tumor sections represented in (E) (n = 12 HPF/group). HPF: high-power field. *: t-test, P = 0.001.
Right: Quantification of MET mean fluorescence intensity in tumor sections represented in (E) (n = 12 HPF/group, fold versus non-irradiated cells, ctrl). *: t-test,
P = 0.00016.
G Representative MET immunohistochemical staining of matched primary and recurrent tumors. Scale bar, 50 µm (40× magnification).
H Histogram representing the number of patient displaying different percentages of MET-expressing cells in their primary or recurrent tumors: negative, 0–5%; low,
6–29%; moderate, 30–69%; high, 70–100% (see also Appendix Table S4).
I Dot plot representing the MET cumulative score (MET-positive cell score + MET staining intensity score) in 19 primary and recurrent tumors (see Appendix Table S4).
*, Wilcoxon, P < 0.02.
Data information: Data are represented as mean  SEM in (F, I) or  CI in (B).
◀
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(ii) MET is a marker of the GSC subpopulation (METhigh) (De Bacco
et al, 2012) (Fig 3A); and (iii) MET promotes radioresistance of
conventional cancer cell lines (De Bacco et al, 2011). Therefore, in
the subset of MET-pos-NS (Appendix Table S3), we investigated the
relationship between MET expression and GSC radioresistance.
Accordingly with our previous data, in vitro LDA (sphere-forming
assay) showed that the METhigh subpopulation, sorted from repre-
sentative MET-pos-NS, was enriched in GSCs (Fig 3B and
Appendix Fig S3A). As assessed by flow cytometry, in MET-pos-NS,
the number of MET-expressing cells, and their MFI, significantly
increased 24 h after irradiation (Fig 3C and Appendix Fig S3B). An
even higher enrichment of MET-expressing cells was observed after
a chronic IR treatment (Fig 3D). Accordingly, in tumors established
by subcutaneous transplantation of MET-pos-NS, the number of
MET-expressing cells and the intensity of staining were significantly
increased 72 h after the last in vivo irradiation (Fig 3E and F).
As MET expression is inducible by IR through NF-jB activation
(De Bacco et al, 2011), we asked whether MET upregulation could
contribute to the enrichment of MET-expressing cells observed after
irradiation. Indeed, MET expression was induced by IR in METhigh
cells sorted from MET-pos-NS, but not in the remaining METneg
subpopulation (Fig EV3A–D). Lack of MET mRNA accumulation in
irradiated METneg cells could be explained by the abundant presence
of miRNA targeting MET (such as miR34a and 23b), which was
previously associated with this subpopulation (De Bacco et al,
2012).
Collectively, these data indicate that MET-expressing GSCs
are radioresistant, likely as a result of concomitant mechanisms,
involving both cell-positive selection and MET transcriptional
upregulation.
MET-expressing cells are enriched in recurrent human GBMs
We asked whether radioresistance of MET-expressing GSCs could
operate in patients’ tumors and be associated with positive selection
under therapeutic pressure. We collected a panel of 19 pairs of
GBMs, each including a primary tumor removed by surgery without
prior treatment, and the matched recurrent tumor, arising after adju-
vant chemoradiotherapy, and again surgically resected (Appendix
Table S4). Remarkably, immunohistochemical analysis of whole
tissues showed that significant MET expression (MET cumulative
score ≥ 2) was detectable in 36% of primary tumors (7/19), but in
84% of recurrent tumors (16/19) (Appendix Table S5). In the major-
ity of cases, the percentage of MET-positive cells and/or the intensity
of MET staining (summed in the cumulative score) increased in the
recurrent as compared with the matched primary tumor (Fig 3G–I
and Appendix Table S5).
These data suggest that, in primary GBMs, cells expressing MET,
being resistant to the standard therapeutic regimen invariably
including radiotherapy, can drive tumor recurrence. Although we
do not provide functional proofs, we reason that the MET-positive
cell population expanded in the recurrent tumor can largely corre-
spond to stem-like cells because: (i) In MET-pos-NS, the MET-nega-
tive cell subpopulation is devoid of stem properties, as previously
shown (De Bacco et al, 2012), and further investigated by in vitro
LDA (Fig 3B and Appendix Fig S3A); and (ii) GSC differentiation is
characterized by loss of MET expression, as shown in vitro (De
Bacco et al, 2012).
The limited size of this cohort did not allow to establish statisti-
cally significant correlations between MET expression and clinical
outcomes such as disease-free or overall survival (Appendix
Table S4). However, in the TCGA dataset, encompassing 401 GBMs
analyzed by whole tissue transcriptional profiling (Cerami et al,
2012; Gao et al, 2013), high MET expression in the primary tumor
was significantly associated with decreased disease-free and overall
survival (Appendix Fig S3C and D).
METhigh GSCs efficiently activate DDR
Radioresistance of the MET-expressing stem-like subpopulation was
further assessed by several experimental approaches. First, in irradi-
ated MET-pos-NS, the cell death response was evaluated by measur-
ing Annexin V incorporation by flow cytometry (Fig 4A). About
36 h after IR, the MET-expressing subpopulation (red) mostly
contained viable cells (Annexin V/DAPI-negative cells, ~70%).
Conversely, the MET-negative subpopulation (blue) displayed a
significant decrease in viable cells as compared with non-irradiated
controls (~25% versus 74%), and a cell redistribution in early and,
mostly, late apoptotic phases (Annexin Vpos/DAPIneg: early apop-
totic; Annexin Vpos/DAPIpos: late apoptotic cells) (Fig 4A). Cell
death of the MET-negative subpopulation was likely due to apopto-
sis, as indicated by analysis of PARP and caspase-3 activation,
which was evident in sorted and irradiated METneg cells, but not in
METhigh cells (Fig 4B).
The biological response to IR was further evaluated in sorted
METhigh and METneg cells. Viability, measured in dose–response
experiments 24 h after IR, was significantly higher in METhigh than
in METneg cells at all doses tested (Fig 4C). Consistently, in radiobi-
ological clonogenic assays, the surviving fraction of METhigh cells
remained almost unchanged even after irradiation with the highest
dose (10 Gy), while that of METneg cells significantly decreased,
tending to exhaust after 10 Gy (Fig 4D and Appendix Fig S4A–C).
Finally, in comet assays performed 24 h after irradiation,
METhigh cells displayed modest DSB accumulation, as compared
with non-irradiated cells, while METneg displayed severe damage
(Fig 4E and Appendix Fig S4D and E).
The radioresistance of the METhigh subpopulation was then
correlated with constitutive DDR activation, as previously assessed
in GSCs prospectively isolated with the CD133 marker (Bao et al,
2006). Indeed, untreated METhigh, but not METneg cells, displayed
constitutive phosphorylation of ATM and Chk2 kinases. After irradi-
ation, ATM phosphorylation was significantly increased in METhigh
cells, but only weakly induced in METneg (Fig 4F and Appendix
Fig S4F). Consistently, RAD51 expression was significantly more
abundant in irradiated METhigh than METneg cells (Fig 4G). Accord-
ingly, 24 h after irradiation, histone H2AX phosphorylation was still
detectable only in METneg cells (Fig 4F).
Collectively, these findings indicate that the positive selection of
METhigh GSC by IR resides on intrinsic radioresistance of this
subpopulation, likely conferred by enhanced basal activity, and effi-
cient hyperactivation of DDR effectors after irradiation.
MET inhibition radiosensitizes GSCs
The above results indicate that MET is a marker of a radioresistant
GSC subpopulation. We thus investigated whether MET signaling
EMBO Molecular Medicine Vol 8 | No 5 | 2016 ª 2016 The Authors
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Figure 4. METhigh GSCs efficiently activate DDR.
A Flow cytometric analysis of Annexin V/DAPI incorporation and MET expression in BT308NS 36 h after IR (5 Gy). Ctrl: non-irradiated cells. Blue: MET-negative cells. Red:
MET-expressing cells.
B Western blot of METneg and METhigh subpopulations sorted from BT452NS, showing activation of PARP (cleaved PARP) and caspase-3 (cleaved casp-3) after IR (5 Gy).
Vinculin was used as a loading control.
C Cell viability of METhigh and METneg subpopulations sorted from BT308NS, measured 96 h after IR (1–10 Gy, fold versus non-irradiated cells, ctrl). *: t-test, P < 0.001.
n = 2.
D Clonogenic assay with METhigh and METneg subpopulations sorted from BT308NS and irradiated (1–10 Gy, fold versus non-irradiated cells, ctrl). *: t-test, P < 0.05. n = 3.
E Neutral comet assay in METhigh and METneg subpopulations sorted from BT308NS, performed 24 h after IR (5 Gy). Ctrl: non-irradiated cells. Comet tail’s length is
proportional to DSB extent.
F Western blot of METneg and METhigh subpopulations sorted from BT308NS, showing constitutive (ctrl) and/or IR-induced phosphorylation of ATM (pATM), Chk2
(pChk2), and H2AX (cH2AX), and accumulation of RAD51, 24 h after IR (5 Gy). Total ATM protein is also shown. b-actin was used as a loading control.
G qPCR of RAD51 expression in METhigh and METneg subpopulations sorted from BT308NS 24 h after IR (5 Gy, fold versus non-irradiated control cells, ctrl). *: t-test,
P = 0.02. n = 3.
Data information: Data are represented as mean  SEM.
Source data are available online for this figure.
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has a functional role in sustaining radioresistance, and whether its
inhibition can radiosensitize GSCs. MET-pos-NS were kept in a stan-
dard EGF/bFGF medium, supplied with HGF to better mimick the
brain (tumor) microenvironment (Kunkel et al, 2001; Xie et al,
2012). In this condition, after irradiation, MET gets hyperphospho-
rylated (Fig EV4A and B), consistently with previous results
obtained in cell lines (Lal et al, 2005; De Bacco et al, 2011). Addi-
tion of HGF to standard culture medium increased radioresistance of
irradiated MET-pos-NS, by preserving viability (Fig 5A and
Appendix Fig S5A and B) and preventing apoptosis (Fig 5B). We
then showed that association of the specific MET inhibitor
JNJ38877605 to IR significantly reduced cell viability and increased
the percentage of apoptotic (Annexin V-positive) cells, as compared
with treatment with IR alone (Fig 5C–E and Appendix Fig S5C and
D). Consistently, caspase-3 activation was barely detectable in cells
treated with IR alone, to become well evident in those treated with
IR and the MET inhibitor (Fig 5F). The effect of MET targeting was
also assessed by the use of alternative inhibitors, including the
MET-specific small-molecule PHA665752, the monovalent form of
the MET monoclonal antibody DN30 (MvDN30) (Pacchiana et al,
2010), and the promiscuous, clinically approved, small-molecule
Crizotinib (targeting MET and ALK kinases). All the above inhibitors
combined with IR similarly reduced cell viability and increased
caspase-3/7 activation, as compared with IR alone (Appendix Fig
S5E–H). These outcomes, observed in whole NS, were obviously
due to the activity of the inhibitors in MET-expressing GSCs and not
in the MET-negative non-stem subpopulation, which, by definition,
lacks the target. Consistently, in radiobiological clonogenic assays
performed with the sorted METneg and METhigh subpopulations, the
surviving fraction of METneg cells treated with IR, already very low,
was not further decreased by MET inhibitors. Conversely, the
surviving fraction of the irradiated METhigh subpopulation was
reduced by MET inhibitors to the levels of the METneg cells (Fig 5G
and Appendix Fig S5I). Finally, in LDA (sphere-forming assay) with
sorted METhigh and METneg subpopulations, the GSC frequency of
the METhigh subpopulation was abated by combination of IR with
the MET inhibitor, while, as expected, the low GSC frequency of the
METneg subpopulation was further decreased only by IR (Fig 5H).
Interestingly, a significant decrease of METhigh GSC frequency was
also observed after treatment with the MET inhibitor alone, indicat-
ing that HGF present in the culture medium plays a role in sustain-
ing self-renewal, as previously shown (Li et al, 2011; De Bacco
et al, 2012) (Fig 5H). However, no apoptosis was expected, and
indeed observed, by treating NS with MET inhibitors alone (Fig 5E
and F and Appendix Fig S5E–H).
The radiosensitizing activity of MET inhibitors was then corre-
lated with the ability to prevent DNA repair. In whole MET-pos-NS,
treatment with IR and the MET inhibitor JNJ38877605 increased
the levels of histone H2AX phosphorylation and the extent of
DSBs, as compared with IR alone (Fig 5I and J and Appendix
Fig S5J and K).
These findings show that MET behaves as a functional marker of
radioresistance, whose inhibition efficiently radiosensitizes METhigh
GSCs.
MET inhibition impairs GSC DDR by preventing AKT-dependent
ATM and p21 activity
We thus asked whether MET inhibition directly impinges on the
molecular mechanisms regulating DDR. We previously showed that,
after irradiation of conventional cell lines, ATM upregulates MET
expression through NF-jB transcription factor (De Bacco et al,
2011). We now show that MET, in turn, unleashes a signal trans-
duction cascade that sustains ATM activity and DDR. We found
that, in irradiated MET-pos-NS kept in the standard EGF/bFGF
medium, addition of HGF increased ATM and Chk2 phosphoryla-
tion, and RAD51 expression (Fig 6A and Appendix Fig S6A).
Conversely, in irradiated MET-pos-NS kept in the medium supplied
with HGF, addition of the MET inhibitor significantly reduced ATM
and Chk2 phosphorylation, and RAD51 expression (Fig 6B and C).
This effect depended specifically on MET inhibition, as shown by
complementary experimental approaches such as: (i) the use of
additional MET inhibitors such as the above-described PHA665752,
Crizotinib, and MvDN30 (Appendix Fig S6B–D), which invariably
Figure 5. MET inhibition radiosensitizes GSCs.
A Cell viability of BT308NS, measured 48 h after IR (2 or 5 Gy) in the absence (mock) or in the presence of 10 ng/ml HGF (fold versus non-irradiated mock treated cells,
mock). Ctrl: non-irradiated cells. *: t-test (5 Gy + HGF) versus (5 Gy), P < 0.0001. n = 2.
B Flow cytometric analysis of Annexin V/DAPI incorporation in BT308NS irradiated (5 Gy) in the absence (mock) or in the presence of HGF. Histograms show the
percentage of Annexin V-positive cells 48 h after IR. Ctrl: non-irradiated cells.
C Cell viability of BT308NS, irradiated in the absence (5 Gy) or in the presence (5 Gy + JNJ) of the MET inhibitor JNJ38877605 (500 nM) and analyzed at the indicated
time points. Vehicle: non-irradiated cells (fold versus vehicle-treated cells at time 0, mock). *: t-test, P < 0.01. n = 2.
D Cell viability as in C, measured 5 days after IR (1–10 Gy, fold versus vehicle-treated cells, mock). *: t-test, P < 0.03. n = 2.
E Flow cytometric analysis of Annexin V/DAPI incorporation in BT308NS irradiated (5 Gy) in the absence (vehicle) or in the presence (JNJ) of JNJ38877605. Histograms
show the percentage of Annexin V-positive cells 36 h after IR. Ctrl: non-irradiated cells. *: t-test (5 Gy + JNJ) versus (5 Gy), P = 0.01. n = 3.
F Western blot of BT308NS showing caspase-3 activation (cleaved casp-3), at the indicated time points after IR in the absence () or in the presence (+) of JNJ38877605.
Vinculin was used as a loading control.
G Clonogenic assay with METneg and METhigh subpopulations sorted from BT308NS, irradiated (5 Gy) in the absence (vehicle) or in the presence of MET inhibitors
(JNJ38877605 and Crizotinib, 500 nM). Ctrl: non-irradiated cells. *: t-test, P < 0.0004. n = 3.
H LDA (sphere-forming assay) with METneg and METhigh subpopulations sorted from BT308NS, measuring GSC frequency after irradiation in the absence (5 Gy) or in the
presence (5 Gy + JNJ) of JNJ38877605. Vehicle: non-irradiated vehicle-treated cells. *: v2 test, P = 0.0002. n = 2.
I Flow cytometric analysis of phosphorylated histone H2AX (cH2AX) in the whole BT308NS at the indicated time points after IR in the absence (5 Gy) or in the presence
(5 Gy + JNJ) of JNJ38877605 (fold versus non-irradiated cells at time 0, mock). *: t-test, P < 0.05. n = 2.
J Neutral comet assay with BT308NS performed 24 h after IR in the absence (5 Gy) or in the presence (5 Gy + JNJ) of JNJ38877605. Vehicle: non-irradiated vehicle-
treated cells. Comet tail’s length is proportional to DSB extent.
Data information: Data are represented as mean  SEM in (A, C–E, G, I) or  CI in (H).
Source data are available online for this figure.
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decreased ATM phosphorylation in irradiated MET-pos-NS; and (ii)
the use of a MET inhibitor in MET-neg-NS (lacking MET protein
expression, Appendix Table S3), which failed to impair ATM phos-
phorylation, thus ruling out off-target effects (Appendix Fig S6E).
We then investigated the mechanistic link between MET and
ATM phosphorylation. In MET-pos-NS, IR induced activation of MET
(see above, Fig EV4A and B) and its two main downstream signaling
pathways, AKT and MAP kinases (MAPK). Phosphorylation of both
AKT and MAPK was dependent of MET, as it was fully prevented by
combining IR with the MET inhibitor (Appendix Fig S6F). We further
showed that AKT was responsible to connect MET to ATM, as an
AKT—but not a MAPK—inhibitor decreased ATM phosphorylation,
and activation of its downstream effectors Chk2 and RAD51 after
irradiation (Fig 6D and Appendix Fig S6G). The pathway linking
AKT to ATM phosphorylation is currently unknown. A likely
candidate to investigate was Aurora kinase A, known to phosphory-
late ATM (Yang et al, 2011). Indeed, in irradiated MET-pos-NS, we
showed that (i) Aurora kinase A phosphorylation on Thr288,
required for enzymatic activation (Walter et al, 2000), was
prevented by the AKT inhibitor LY294002 (Fig 6E and Appendix Fig
S6H), as well as by the MET inhibitor (Fig 6F and Appendix Fig S6I);
(ii) Aurora kinase A phosphorylation was increased by HGF (Fig 6G
and Appendix Fig S6J); and (iii) Aurora kinase A inhibition by
its specific small-molecule inhibitor MLN8237 prevented ATM
phosphorylation (Fig 6H and Appendix Fig S6K). Consistently, AKT
or Aurora kinase A inhibitors mimicked the radiosensitizing activity
of the MET inhibitor, as shown in viability experiments (Fig 6I and
Appendix Fig S6L and M).
The role of the AKT pathway as a crucial player of MET-induced
radioresistance was further supported by p21 analysis. It is known
that, when it is phosphorylated by AKT on Thr145, p21 is retained
in the cytoplasm and exerts anti-apoptotic functions; in the absence
of this phosphorylation, p21 translocates into the nucleus to block
the cell cycle (Abbas & Dutta, 2009). Indeed, we showed that, in
irradiated MET-pos-NS kept in the standard EGF/bFGF medium,
addition of HGF induced p21 phosphorylation on Thr145 (Fig 7A)
and its cytoplasmic accumulation (Fig 7A). In a complementary
experiment, in irradiated MET-pos-NS kept in the medium supplied
with HGF, addition of the MET inhibitor prevented p21 phosphory-
lation on Thr145 (Fig 7B and Appendix Fig S7A), and induced its
nuclear translocation, as shown by Western blot and immunofluo-
rescence analysis (Fig 7C–E and Appendix Fig S7B and C). Consis-
tently, when MET-pos-NS were irradiated in the presence of the
MET inhibitor, cell cycle was arrested in the G2-M phase (Fig 7F
and Appendix Fig S7D) and apoptosis was unleashed (see above,
Fig 5E and F and Appendix Fig S5E–H).
Collectively, these data indicate that MET supports DDR via AKT acti-
vation, which, on its turn, sustains the ATM pathway for DNA repair,
and p21 cytoplasmic retention, connected with anti-apoptotic functions
(Fig 7G). Impairment of these signaling circuits provides a mechanistic
explanation for the radiosensitizing effect of MET inhibitors.
MET inhibition radiosensitizes GSC-derived GBMs by
GSC depletion
We then generated GBMs by in vivo transplantation of MET-pos-NS,
to investigate whether combination with MET inhibitors could
increase the efficacy of radiotherapy by contributing to deplete GSCs.
As assessed, the MET inhibitor JNJ38877605 crosses the blood–brain
barrier (Appendix Fig S8A). GBMs were then established by intracra-
nial xenotransplantation of BT463NS. Ten days after NS injection,
mice were randomized into four treatment groups: (i) vehicle, (ii) IR
(2 Gy × 3 days), (iii) JNJ38877605, supplied for 30 days, and (iv)
combination therapy (combo, IR and JNJ38877605 as above).
Approximately 60 days after the beginning of treatment, at the onset
of severe neurological symptoms in controls, mice were sacrificed
and brains were analyzed by epifluorescence imaging (Fig 8A).
Combination therapy dramatically reduced tumor growth, measured
as GFP intensity, as compared with IR or MET inhibitor alone
(Fig 8B). In a secondmodel, tumors were established by subcutaneous
Figure 6. MET inhibition impairs AKT-dependent ATM activity.
A Western blot of BT463NS showing phosphorylation of ATM (pATM) and Chk2 (pChk2), and accumulation of RAD51 at the indicated time points after IR in the absence
(5 Gy) or in the presence (5 Gy + HGF) of HGF (10 ng/ml). Total ATM is also shown. H3 was used as a loading control.
B Western blot of BT308NS showing phosphorylation of ATM (pATM) and Chk2 (pChk2) and accumulation of RAD51 at the indicated time points after IR in the absence
(5 Gy) or in the presence (5 Gy + JNJ) of the MET inhibitor JNJ38877605 (500 nM). Total ATM is also shown. b-actin was used as a loading control. Veh: non-irradiated
vehicle-treated cells.
C Densitometric analysis of ATM phosphorylation shown in (B). *: t-test, P < 0.01. n = 3.
D Western blot of BT308NS showing phosphorylation of ATM, Chk2, and AKT (pAKT) and accumulation of RAD51 24 h after IR (5 Gy) in the absence (vehicle, veh) or in
the presence of MAPK (PD98059, 20 lM), AKT (Ly294002, 20 lM), MET (JNJ38877605), or ATM (CGK733, 10 lM) inhibitors. Total ATM and AKT are also shown. b-actin
was used as a loading control. Ctrl: non-irradiated cells.
E Western blot of BT463NS showing phosphorylation of ATM, Chk2, and Aurora kinase A (pAurora A) at the indicated time points after IR in the absence (5 Gy) or in the
presence (5 Gy + Ly) of the AKT inhibitor Ly294002. Total ATM and Aurora kinase A are also shown. H3 was used as a loading control. Veh: non-irradiated vehicle-
treated cells.
F Western blot of BT308NS showing phosphorylation of Aurora kinase A at the indicated time points after IR in the absence (5 Gy) or in the presence (5 Gy + JNJ) of
JNJ38877605. Total Aurora kinase A is also shown. H3 was used as a loading control. Veh: non-irradiated vehicle-treated cells.
G Western blot of BT463NS showing phosphorylation of Aurora kinase A at the indicated time points after IR in the absence (5 Gy) or in the presence (5 Gy + HGF) of
HGF. Total Aurora kinase A is also shown. H3 was used as a loading control (the same control applies to both panel A and G).
H Western blot of BT308NS showing phosphorylation of ATM and Aurora kinase A at the indicated time points after IR in the absence (5 Gy) or in the presence
(5 Gy + MLN) of the Aurora kinase A inhibitor MLN8237 (20 lM). Total ATM and Aurora kinase A are also shown. H3 was used as a loading control. Veh: non-
irradiated vehicle-treated cells.
I Cell viability of BT308NS, measured 72 h after IR (5 Gy) in the absence (vehicle) or in the presence of MET (JNJ38877605), Aurora kinase A (MLN8237), or AKT
(Ly294002) inhibitors (fold versus non-irradiated vehicle-treated cells, mock). *: t-test (5 Gy + inhibitor) versus (5 Gy + vehicle), P < 0.01. n = 2.
Data information: Data are represented as mean  SEM.
Source data are available online for this figure.
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Figure 7. MET inhibition promotes p21 nuclear translocation.
A Western blot of BT371NS showing p21 phosphorylation (pp21Thr145) in cytoplasmic lysates immunoprecipitated with p21 antibodies at the indicated time points after
IR in the absence (5 Gy) or in the presence (5 Gy + HGF) of HGF (10 ng/ml).
B Western blot of BT463NS showing p21 phosphorylation (pp21Thr145) in cytoplasmic lysates immunoprecipitated with p21 antibodies at the indicated time points after
IR in the absence (5 Gy) or in the presence (5 Gy + JNJ) of the MET inhibitor JNJ38877605 (500 nM).
C Western blot of BT308NS showing p21 localization in cytoplasmic/nuclear extracts at the indicated time points after IR in the absence (5 Gy) or in the presence
(5 Gy + JNJ) of JNJ38877605. Vinculin and lamin B were used as loading controls for cytoplasmic and nuclear fractions, respectively.
D Representative immunofluorescence staining of p21 (red) on BT308NS cells 3 h after IR (5 Gy) in the absence (vehicle) or in the presence (JNJ) of JNJ38877605. Ctrl:
non-irradiated cells. Nuclei are counterstained with DAPI (blue). Scale bar, 10 µm (63× magnification).
E Quantification of the percentage of cells showing p21 cytoplasmic or nuclear localization in BT308NS represented in (D) (n = 10 HPF/group). HPF: high-power field.
*: t-test (5 Gy + JNJ) versus (ctrl or 5 Gy), P < 0.0001.
F Cell cycle analysis of BT314NS, performed 24 h after IR in the absence (5 Gy) or in the presence (5 Gy + JNJ) of JNJ38877605. Vehicle: non-irradiated cells. *: one-way
ANOVA, P = 0.008. n = 3.
G Schematic representation of the MET-driven signaling pathways that sustain DNA repair and prevent apoptosis and cell cycle arrest.
Data information: Data are represented as mean  SEM.
Source data are available online for this figure.
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transplantation of BT308NS, displaying a GBM-like morphology
(Appendix Fig S8B), and were treated as above (JNJ38877605 was
administered for 15 days). Tumors treated with vehicle, or the
MET inhibitor alone, reached the experimental endpoint (tumor
volume = 1,600 mm3) within 18 or 32 days, respectively. Tumors
treated with IR alone remained stable for 40 days after beginning of
the treatment, leading to the experimental endpoint within 63 days.
Remarkably, tumors treated with the combination therapy showed
clinical regression (volume reduction > 50% as compared with day
0), which persisted until 40 days, leading to the experimental
endpoint 90 days after beginning of the treatment (Fig 8C and D). A
significant growth inhibition (~2-fold) by combination therapy as
compared with radiotherapy alone was observed also in tumors
generated by transplantation of BT371NS, although these tumors
were not arrested by any therapy (Appendix Fig S8B–D).
Next, we investigated whether combination treatment led to
decreased GSC frequency. As depicted in Fig 8E, in an independent
experiment, tumors were generated by BT308NS subcutaneous trans-
plantation, treated as above, explanted 10 days after beginning of the
treatment, that is, when regression was observed (Appendix Fig S8E),
and analyzed by LDA. Both in vitro clonogenic (Fig 8F) and in vivo
tumorigenic (Fig 8G–I) LDA indicated a significant GSC frequency
decrease in tumors treated with combination therapy, as compared
with controls or radiotherapy (or the MET inhibitor) alone. Of note,
in vitro but not in vivo LDA (p1) allowed to detect an increased GSC
frequency after radiotherapy alone. This is expected, as in vivo LDA,
measuring tumorigenic potential, requires at least two serial passages
(p2) to highlight positive selection of GBM stem-like cells by irradia-
tion, as shown above (Figs 2F and EV2A and B). However, in this
experiment, further passaging was prevented by the minimal volume,
and poor cell viability, of tumors generated by the first passage (p1)
after combination therapy (Appendix Fig S8F).
Collectively, these data indicate that radiosensitization of GBM
by MET inhibitors not only impairs tumor growth, but also
depletes the GSC subpopulation responsible for tumor generation
and recurrence.
Discussion
Radioresistance is a well-known pitfall of GBM therapy (Squatrito &
Holland, 2011). The responsible cell subpopulation(s), as well as the
underlying genetic and molecular mechanisms, are still poorly
understood. Pioneering work has associated radioresistance of GBM
and other tumors with the cancer stem cell phenotype, particularly
with the intrinsic ability to efficiently activate DDR (Bao et al, 2006;
Phillips et al, 2006b; Diehn et al, 2009; Pajonk et al, 2010; Cheng
et al, 2011; Vlashi & Pajonk, 2014; Ahmed et al, 2015). In GBM, this
property is likely inherited from the cell of origin, a neural stem/
progenitor cell (Blanpain et al, 2011). More recently, GSC radioresis-
tance has been associated with the GBM mesenchymal profile,
implying a causal role for the subtype-specific genetic lesions and/or
signaling circuits (Bhat et al, 2013). The latter findings are consistent
with the evidence that the GBM mesenchymal profile and the epithe-
lial–mesenchymal transition in general overlap with the stem cell
phenotype (Phillips et al, 2006a; Scheel & Weinberg, 2012) and thus
with inherent radioresistance. In the panel of twenty NS analyzed in
this study, radioresistance was found to be a common property,
displayed by mesenchymal as well as by classical or proneural NS.
In classical NS, the typical EGFR amplification could play a promi-
nent role in conferring radioresistance, as indicated by previous
studies (Squatrito & Holland, 2011). In mesenchymal and proneural
NS, usually lacking EGFR amplification, we investigated whether a
prominent role could be played by the wild-type MET oncogene,
which was previously associated with the GBM mesenchymal profile
(Phillips et al, 2006a; Verhaak et al, 2010; De Bacco et al, 2012), and
is usually expressed in a mutually exclusive fashion with EGFR
(Verhaak et al, 2010; De Bacco et al, 2012).
Building on previous studies showing that MET is a marker of a
GSC subtype, which identifies and sustains the stem phenotype (Li
et al, 2011; De Bacco et al, 2012; Joo et al, 2012), we now show that
MET is a functional marker of GSC radioresistance. Indeed, we found
that IR positively selects METhigh GSCs and that the radioresistant
phenotype of these cells correlates with high basal expression levels
of ATM, Chk2, and RAD51, which likely prime cells to efficiently
activate DDR. As a result, METhigh GSCs, but not METneg non-stem
cells, can rapidly repair DNA damage and successfully survive IR.
The protective role of MET likely operates in human GBMs
treated with the standard combination of radio- and chemotherapy
with the alkylating agent temozolomide (Stupp et al, 2009). Indeed,
in the patients’ cohort analyzed, MET expression is enriched in the
recurrent tumors, as compared with the matched primary. This indi-
cates the expansion of MET-expressing (stem-like) cells, likely bene-
fitting of a selective advantage under therapeutic pressure and
Figure 8. MET inhibition radiosensitizes GSC-derived GBMs by GSC depletion.
A Timeline of therapeutic treatments undergone by mice intracranially injected with BT463NS.
B Left: Representative images of ex vivo epifluorescent GFP signal of intracranial tumors, generated by injection of BT463NS, and explanted 62 days after IR in the
absence (2 Gy × 3 days) or in the presence (combo) of the MET inhibitor JNJ38877605 (50 mg/kg). Right: Quantification of epifluorescent GFP signal from tumors
represented on the left (n = 4/condition). Vehicle: non-irradiated vehicle-treated tumors. *: one-way ANOVA, P = 5.5 × 105.
C Growth curves of tumors, generated by subcutaneous injection of BT308NS, irradiated in the absence (2 Gy × 3 days) or in the presence (combo) of JNJ38877605,
which was administered for 15 days as indicated (n = 7/condition). Vehicle: non-irradiated vehicle-treated tumors. *: one-way ANOVA, P = 0.0006.
D Survival analysis of mice bearing tumors generated and treated as in (C). Black dot: censored mouse. Log-rank (Mantel-Cox) test (combo) versus (2 Gy × 3 days),
P = 0.0019.
E Experimental design to measure GSC frequency in tumors treated as in (C) (JNJ was administered for 10 days). Explanted tumors were dissociated, and viable cells
were tested by in vitro sphere-forming LDA or in vivo single-passage (p1) LDA.
F In vitro LDA (sphere-forming) measuring GSC frequencies as described in (E) (n = 3/condition). *: v2 test, P < 105.
G Tumor incidence in the in vivo LDA performed on tumors generated and treated as described in (E).
H Histogram showing GSC frequencies measured by in vivo LDA, as described in (E). *: v2 test, P = 5.47 × 106.
I Table showing GSC frequencies measured by in vivo LDA, represented in (H).
Data information: Data are represented as mean  SEM in (B, C) or  CI in (F, H, I).
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possibly mediating the well-known radiotherapeutic refractoriness
of the recurrent tumor. Not surprisingly, analysis of the TCGA
dataset indicates that high MET expression in primary GBMs is
associated with primary therapeutic resistance (decreased disease-
free survival) and poorer prognosis.
This evidence compelled us to investigate the possibility to over-
come GSC radioresistance by MET inhibition. Indeed, we show that
MET small-molecule kinase inhibitors, or inhibitory antibodies,
combined with IR, decrease the radioresistance of GSCs (METhigh)
to levels comparable with non-stem (METneg) cells. We report for
the first time that, in irradiated NS, MET inhibition impairs ATM
phosphorylation and the ensuing DDR, resulting in dramatic reduc-
tion of RAD51 expression, and DNA repair failure. Till now, the
relationship between receptor tyrosine kinase signaling and DDR
has been poorly characterized. We thus sought to reconstruct the
mechanistic link between MET and ATM inhibition, establishing an
essential role for AKT. We show that both AKT and MAP kinases,
two prominent signal transducers downstream MET, are hyperphos-
phorylated together with MET in irradiated cells. AKT and MAP
kinase hyperactivation depends of MET, as it is prevented by
combining IR with MET inhibitors. Moreover, IR combination with
either MAPK or AKT inhibitors showed that AKT, but not MAPK, is
the likely connection between MET and ATM phosphorylation.
Interestingly, AKT activation has been previously correlated with
poor prognosis in GBM (Phillips et al, 2006a) and with radioresis-
tance in other brain tumors (medulloblastomas) (Hambardzumyan
et al, 2008). However, it was currently unknown whether AKT can
directly affect ATM phosphorylation. We now show that a conceiv-
able intermediary is Aurora kinase A, known to be both an AKT
substrate and a kinase active on ATM (Shiloh & Ziv, 2013), but not
yet involved in DDR modulation by growth factor signaling.
We also show that AKT activation by MET sustains radioresis-
tance by modulating p21 activity. It is known that, after phosphory-
lation by AKT, p21 is retained in the cytoplasm and inhibits
apoptosis-related transducers and effectors, including procaspases
and caspases (Abbas & Dutta, 2009). We show that, after irradiation
in the presence of HGF, p21 is phosphorylated and mainly localized
in the cytoplasm, whereas, when MET inhibitors are combined with
irradiation, p21 phosphorylation by AKT is prevented, and the
protein translocates into the nucleus. Accordingly with what
observed in this study, p21 nuclear translocation implies loss of
anti-apoptotic activity and inhibition of the cell cycle (Abbas &
Dutta, 2009). It could be further speculated that, in the presence of
MET inhibitors, nuclear p21 prevents CDK1 from stimulating
homologous recombination via the BRCA2–RAD51 complex (Esashi
et al, 2005). Collectively, the above data suggest that MET
inhibition radiosensitizes GSCs by blocking AKT activation, which
results in (i) decreased ATM activity and (ii) conversion of p21
function from prevention of apoptosis to inhibition of cell cycle and
DNA repair.
This study offers preclinical evidence that MET inhibitors, associ-
ated with radiotherapy, not only cause tumor shrinkage, but also
reduce the content of GSCs, the source of tumor recurrence. Evalua-
tion of the therapeutic effect on cancer stem cells is essential to
establish the efficacy of a treatment, but, regretfully, it is often disre-
garded by the conventional settings testing either radiochemother-
apy and/or targeted agents (Baumann et al, 2008; Krause et al,
2011; Vlashi & Pajonk, 2014).
To target MET in GBM patients, clinically approved MET inhibi-
tors (such as the multi-kinase inhibitor Crizotinib) are available,
and new compounds, either small molecules or antibodies, are
under development (Peters & Adjei, 2012; Vigna & Comoglio, 2015).
Interestingly, beside radiosensitization, MET inhibitors could
display therapeutic activity per se, interfering with different aspects
of GSC involvement in tumorigenesis. Indeed, MET inhibitors can
impair the GSC phenotype, sustained through signaling stimulated
by the ligand HGF (Li et al, 2011; De Bacco et al, 2012). Interest-
ingly, HGF is provided by paracrine circuits and often produced in
autocrine loops by GBM cells (Xie et al, 2012) and NS
(Appendix Table S3). Consistently—even alone—MET inhibition
can impair tumor growth in vivo. Moreover, MET inhibitors could
be highly effective in the small percentage of patients (3%) where
MET is amplified (Brennan et al, 2013) and could confer “oncogene
addiction” to GSCs (Boccaccio & Comoglio, 2014). Finally, MET
inhibition could target neoangiogenic GBM vessels (Michieli et al,
2004), thus impairing the perivascular niche, known to be essential
for GSC maintenance (Calabrese et al, 2007).
Like any other targeted therapy, the success of MET inhibitors or
antibodies will ultimately depend on the precise identification of
patients expressing the functional target. According to the analysis
presented in this study and previous studies (Koochekpour et al,
1997; De Bacco et al, 2012), it is expected that a relevant fraction of
GBM patients (~40%) will be MET positive. In the clinical setting,
integration of protein expression and genetic data, obtained by anal-
ysis of GBM tissues or more accessible biological samples, will be
required to discriminate patients that could benefit from MET
targeted therapies.
Materials and Methods
NS derivation and culture from human GBM
From surgical samples of consecutive primary GBM (provided by
the Fondazione IRCCS Istituto Neurologico C. Besta, according to a
protocol approved by the institutional Ethical Committee), NS were
derived as described (De Bacco et al, 2012) and plated at clonal
density in standard medium containing human recombinant bFGF
(20 ng/ml) and EGF (20 ng/ml). For in vitro experiments, NS were
kept in a modified medium with EGF and bFGF (10 ng/ml), supple-
mented with human recombinant HGF (10 ng/ml), unless otherwise
indicated. Both media sustain the same NS proliferation rate
(Appendix Fig S9A). NS-derived pseudodifferentiated cells were
obtained by culture in medium deprived of growth factors and
supplemented with 2% FBS, in pro-adherent culture dishes, for
7 days.
NS irradiation and treatment
NS were irradiated with a 200 kV X-ray blood irradiator (Gilardoni),
and a 1 Gy/min dose rate. In some experiments, HGF (20 ng/ml)
was added to standard medium 1 h before irradiation. For MET
targeting, the kinase inhibitors JNJ38877605 (500 nM, Janssen Phar-
maceutica) (De Bacco et al, 2011), PHA665752 (500 nM; Tocris
Cookson Ltd), or Crizotinib (500 nM, Sequoia Research Products)
were added to cells 2 h before irradiation. Inhibitors for MAPK
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(PD98059: 20 lM, Calbiochem), AKT (Ly294002: 20 lM, Calbio-
chem), Aurora kinase A (MLN8237: 20 lM, Millennium Pharmaceu-
ticals), ATM (CGK733: 10 lM, Sigma) were added 1–4 h before IR.
DMSO was used as vehicle.
Xenografts models and treatments
All animal procedures were approved by the Italian Ministry of
Health and the internal Ethical Committee for Animal Experimenta-
tion. NS-derived single-cell suspensions were injected into 6- to
8-week-old female NOD.CB17-Prkdcscid/NcrCr mice. Subcutaneous
tumor diameters were measured every 3 days by caliper. For ortho-
topic transplantation, cells expressing a bicistronic luciferase-GFP
construct were delivered into the right corpus striatum by stereotac-
tic injection. Intracranial tumors were monitored by biolumines-
cence (BLI) imaging (IVIS SpectrumCT, Caliper Life Sciences) once
a week. For radiosensitization experiments, mice were randomized
by LAS software (Baralis et al, 2012). IR was delivered by
TomoTherapy HD or the equivalent Hi-Art (Accuray, Inc.).
JNJ38877605 (50 mg/kg) was administered by daily oral gavage
starting the day before IR. Mice were monitored daily and sacrificed
in case of evident suffering. In survival experiments (subcutaneous
xenografts), mice were sacrificed when tumor size reached
1,600 mm3; animals euthanized before this endpoint were included
in survival curves as censored observations. In the orthotopic
model, mice were euthanized at day 62 after start of the treatment
(onset of neurological symptoms in the control group). Explanted
brains were immediately analyzed for GFP signal detection
(ex 465 nm, em 520 nm; IVIS
 SpectrumCT).
Limiting dilution assay in vivo
In vivo limiting dilution assay (LDA) was performed to evaluate
the GSC frequency in subcutaneous xenografts. Tumors were
explanted and dissociated to re-derive tumor cells, which were
cultured in standard medium as above. After recovery (about
10 days), single-cell suspensions of viable cells (trypan blue exclu-
sion test) were injected in the right flank of mice at the following
doses: 10, 102, 103, or 104 cells in 100 ll v/v PBS/Matrigel (six
mice/condition). The GSC frequency was evaluated on the effi-
ciency of secondary xenograft formation through the extreme
limiting dilution assay (ELDA) software (http://bioinf.wehi.edu.
au/software/elda/).
Statistical analysis
Values were expressed as mean  standard error of the mean (SEM)
or confidence intervals 95% (CI). In vitro experiments were repeated
at least twice in quadruplicate. Statistical analyses were performed
using GraphPad Prism Software (GraphPad Software Inc.). Unpaired
two-sided Student’s t-test, one-way analysis of variance (ANOVA),
Wilcoxon, Mantel–Cox, or chi-squared tests were used as indicated.
A P-value < 0.05 was considered to be significant.
Detailed methods are available as Appendix Supplementary
Methods.
Expanded View for this article is available online.
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The paper explained
Problem
GBM, the most aggressive and common primary brain tumor, usually
remains refractory to the best standard of care, entailing radiotherapy
as a mainstay and, often, as the only treatment option. GBM radiore-
sistance has been associated with distinctive properties of the GBM
stem-like subpopulation: after irradiation, while bulk cells accumulate
DNA damage and die, stem-like cells efficiently activate DNA repair
mechanisms and survive, driving tumor recurrence. A deeper under-
standing of the mechanisms of GBM stem-like cell radioresistance is
needed, in order to identify druggable targets for radiosensitization
and long-term effective therapeutic response.
Results
By analyzing a large panel of GBM stem-like cells in vitro propagated
as neurospheres, we provide evidence that radioresistance is
significantly higher in GBM stem-like cells than in their differentiated
counterpart (including cells derived from stem-like cell pseudodif-
ferentiation). We show that the levels of radioresistance are similar in
stem-like cells displaying different genetic alterations or transcrip-
tional profiles, which characterize distinct GBM subtypes (classical,
proneural, and mesenchymal). However, in a subset of neurospheres,
radioresistance is associated with expression of MET, the HGF tyrosine
kinase receptor. MET-expressing stem-like cells are positively selected
by ionizing radiation in vitro and, possibly, also in vivo, as assessed in
a cohort of human patients including 20 cases of surgically removed
primary GBMs and their matched recurrences.
We then provide a mechanistic analysis of the still elusive signaling
pathways through which MET promotes radioresistance: one sustains
activation of ATM kinase, which orchestrates DNA repair; the other
induces p21 cytoplasmic retention, associated with antiapoptotic
functions. Finally, in vitro and in vivo, we show that MET inhibition
radiosensitizes tumors, by improving the overall control of tumor
growth, and, most importantly, by converting the danger of GBM
stem-like cell-positive selection into the benefit of their depletion.
Impact
We provide preclinical evidence that MET drugs can be combined
with radiotherapy to undermine the inherent radioresistance of GBM
stem-like cells, thus increasing the efficacy of radiotherapy in tumor
growth control and, possibly, in preventing recurrence.
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